Clinical Trials Logo

Kidney Cancer clinical trials

View clinical trials related to Kidney Cancer.

Filter by:

NCT ID: NCT00915993 Recruiting - Kidney Cancer Clinical Trials

MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer

Start date: May 2009
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with stage IV kidney cancer.

NCT ID: NCT00908739 Withdrawn - Kidney Cancer Clinical Trials

Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer

Start date: May 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for localized kidney cancer.

NCT ID: NCT00900536 Completed - Kidney Cancer Clinical Trials

DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE

Start date: July 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to sorafenib. PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.

NCT ID: NCT00900276 Completed - Bladder Cancer Clinical Trials

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

Start date: June 2006
Phase:
Study type: Observational

RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in patients with kidney cancer or cancer of the urothelium and in healthy participants.

NCT ID: NCT00900042 Completed - Kidney Cancer Clinical Trials

SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

Start date: July 1993
Phase: N/A
Study type: Observational

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

NCT ID: NCT00899860 Terminated - Kidney Cancer Clinical Trials

Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer

Start date: September 2003
Phase: N/A
Study type: Observational

RATIONALE: Studying the genes and proteins expressed in tissue samples from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is evaluating gene and protein expression in normal tissue and tumor tissue from patients who have undergone surgery for kidney cancer.

NCT ID: NCT00896467 Terminated - Breast Cancer Clinical Trials

Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy

Start date: September 2007
Phase: N/A
Study type: Observational

RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may help doctors learn more about the psychological and emotional results of being in a clinical trial. PURPOSE: This clinical trial is comparing the psychological and emotional impact of participating in a randomized clinical trial with the impact of standard treatment in patients with metastatic cancer.

NCT ID: NCT00896454 Completed - Breast Cancer Clinical Trials

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Start date: November 16, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium </= 11.5 mg/dL (2.9 millimoles /L) by day 10.

NCT ID: NCT00873236 Recruiting - Kidney Cancer Clinical Trials

MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer

Start date: April 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Comparing results of MRI scans done after bevacizumab may help doctors predict a patient's response to treatment and help plan the best treatment. It is not yet known whether giving bevacizumab alone is more effective than giving bevacizumab together with interferon alpha-2a in detecting kidney cancer. PURPOSE: This randomized phase II trial is studying MRI scans of blood vessel changes caused by bevacizumab to see how well it works compared with bevacizumab given together with interferon alpha-2a in treating patients with stage III or stage IV kidney cancer.

NCT ID: NCT00866320 Completed - Kidney Cancer Clinical Trials

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

Start date: February 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with metastatic kidney cancer that has not responded to sunitinib or bevacizumab.